US Pharma MarketingGilead’s pill posts stronger remission rates than Entyvio in ulcerative colitis
Gilead’s oral α4β7 drug emvistegrast posts 31% UC remission in Ph2 SWIFT, topping Entyvio cross-trial; Phase 3 set for 2027. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in…
Gilead Sciences is to start late-stage trials of its oral α4β7 inhibitor in ulcerative colitis next year, after data from a Phase 2 dose-finding trial suggested that the drug looked better than rival products.
After ...
Source: Endpoints News